Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 4, 2011

View Archived Issues

Several inhibitors of botulinum neurotoxins presented at Pacifichem 2010

Replacement of alpha-L-iduronidase at birth shows promise to treat mucopolysaccharidosis

Sorafenib monotherapy ineffective in patients with advanced melanoma

KPT-127 is toxic to hematological cancer cells

Astellas Pharma reflects on Q2 of fiscal year 2010

AstraZeneca researchers patent novel DPPI inhibitors

New antagonists of melanin-concentrating hormone MCH1 receptor identified

New ligands of trace amine-associated receptor 1 described

Repros Therapeutics receives approval for phase IIb Androxal trial

OSI scientists discover novel anticancer FADK 1 inhibitors

Inspire Pharma reports on second phase III denufosol trial in cystic fibrosis

Labopharm and Purdue Pharma amend license agreement for Ryzolt

ReCyte Therapeutics to develop treatments for cardiovascular and blood diseases

Advanced Cell Technology cleared to test MA-09-HRPE in AMD

Janssen claims new inhibitors of fatty-acid amide hydrolase 1

Veridex, Massachusetts General Hospital and Johnson & Johnson join to develop CTC technology

Senesco's SNS01-T obtains FDA orphan drug status in multiple myeloma

Juventas begins phase II trial of JVS-100 for critical limb ischemia

FDA approves Tibotec's Intelence 200-mg formulation

BTZO-1 and BTZO-2 exhibit cardioprotective activity in vitro

Celera files premarketing approval application with FDA for KIF6 Genotyping Assay

POL-6326 is well tolerated and effectively mobilizes hematopoietic stem cells in phase II trial

Stryker completes purchase of Boston Scientific's neurovascular business

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...